The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial Infarction
Abstract
Background The therapeutic benefit of thrombolytic therapy has been shown to correlate directly with completeness (TIMI grade 3 flow) and speed of reperfusion of the infarct-related coronary artery. The purpose of the RAPID II study was to determine whether a double-bolus regimen of reteplase, a recently developed deletion mutant of wild-type tissue plasminogen activator, could improve 90-minute coronary artery patency rates achieved with the most successful standard regimen, an “accelerated” front-loaded infusion of alteplase. Methods and Results Three hundred twenty-four patients with acute myocardial infarction were randomized to receive (along with intravenous heparin and aspirin) either a 10 plus 10 megaunits double bolus of reteplase or front-loaded alteplase. The primary end point of “patency at 90 minutes, graded according to the TIMI classification” was centrally assessed in a blinded fashion. Infarct-related coronary artery patency (TIMI grade 2 or 3) and complete patency (TIMI grade 3) at 90 minutes after the start of thrombolytic therapy were significantly higher in the reteplase-treated patients (TIMI grade 2 or 3: 83.4% versus 73.3% for front-loaded alteplase-treated patients, P =.03; TIMI grade 3: 59.9% versus 45.2%, P =.01). At 60 minutes, the incidence of both, patency and complete patency, was also significantly higher in reteplase-treated patients (reteplase versus alteplase, TIMI grade 2 or 3: 81.8% versus 66.1%, P =.01; TIMI grade 3: 51.2% versus 37.4%, P <.03). Reteplase-treated patients required fewer acute additional coronary interventions (13.6% versus 26.5%, P <.01), and 35-day mortality was 4.1% for reteplase and 8.4% for alteplase ( P =NS). There were no significant differences between reteplase and alteplase in bleedings requiring a transfusion (12.4% versus 9.7%) or hemorrhagic stroke (1.2% versus 1.9%). Conclusions Reteplase, when given as a double bolus of 10 plus 10 megaunits to patients with acute myocardial infarction, achieves significantly higher rates of early reperfusion of the infarct-related coronary artery and requires significantly fewer acute coronary interventions than front-loaded alteplase without an apparent increased risk of complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial Infarction
DeWood, M. A., Spores, J., Notske, R., Mouser, L. T., Burroughs, R., Golden, M. S., & Lang, H. T. (1980) · New England Journal of Medicine · doi:10.1056/nejm198010163031601 · Cited by 2,740
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION
GRUPPOITALIANOPERLOSTUDIODELL (1986) · The Lancet · doi:10.1016/s0140-6736(86)92368-8 · Cited by 2,440
(1993) · New England Journal of Medicine · doi:10.1056/nejm199311253292204 · Cited by 1,866
TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION
Wilcox, R. G., Olsson, C. G., Skene, A. M., Von Der Lippe, G., Jensen, G., Hampton, J. R., & For The Asset Study Group (1988) · The Lancet · doi:10.1016/s0140-6736(88)92656-6 · Cited by 1,153
Lilleyman, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90079-2 · Cited by 565
ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY
Hirose, S., Uemura, Y., Fujishita, M., Kitagawa, T., Yamashita, M., Imamura, J., Ohtsuki, Y., Taguchi, H., & Miyoshi, I. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90081-4 · Cited by 556
Michels, K. B., & Yusuf, S. (1995) · Circulation · doi:10.1161/01.cir.91.2.476 · Cited by 326
Cited by
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
ACC/AHA guidelines for the management of patients with acute myocardial infarction
Committee Members, Ryan, T. J., Anderson, J. L., Antman, E. M., Braniff, B. A., Brooks, N. H., Califf, R. M., Hillis, L. D., Hiratzka, L. F., Rapaport, E., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00392-0 · Cited by 1,850
Self-citationNetwork meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction
(1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371603 · Cited by 676
Metadata
- Authors
- Bode, C., Smalling, R. W., Berg, G., Burnett, C., Lorch, G., Kalbfleisch, J. M., Chernoff, R., Christie, L. G., Feldman, R. L., Seals, A. A., & Weaver, W. D.
- Venue
- Circulation
- Published
- 1996-09
- Volume
- 94
- Issue
- 5
- Pages
- 891-898
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1963950792
- Cited by
- 371
- References
- 18
- FWCI
- 32.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial Infarction. https://app.cochat.ai/papers/10.1161/01.cir.94.5.891
- The paper
- Bode, C., Smalling, R. W., Berg, G., Burnett, C., Lorch, G., Kalbfleisch, J. M., Chernoff, R., Christie, L. G., Feldman, R. L., Seals, A. A., & Weaver, W. D. (1996). Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial Infarction. Circulation. https://doi.org/10.1161/01.cir.94.5.891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.